There were 1,074 press releases posted in the last 24 hours and 402,540 in the last 365 days.

MannKind Corporation to Present at Upcoming Conferences

WESTLAKE VILLAGE, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for patients with diseases such as diabetes, announced today that it will present at upcoming conferences.

  • Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 9:35 am (ET) at the Lotte New York Palace in New York
  • Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 9:10 am (ET) at the InterContinental New York Barclay Hotel in New York

Presenting from the Company will be its Chief Executive Officer, Michael Castagna.    

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com.

About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes.  MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Company Contact:
Rose Alinaya
SVP Investor Relations
818-661-5055
ir@mannkindcorp.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.